Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $.001 per share
-
Shares outstanding
-
31.8M
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
433K
-
Shares change
-
-1.05M
-
Total reported value, excl. options
-
$131K
-
Value change
-
-$1.2M
-
Number of buys
-
12
-
Number of sells
-
-3
-
Price
-
$0.30
Significant Holders of Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) as of Q2 2025
25 filings reported holding MBRX - Moleculin Biotech, Inc. - Common Stock, par value $.001 per share as of Q2 2025.
Moleculin Biotech, Inc. - Common Stock, par value $.001 per share (MBRX) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 433K shares
of 31.8M outstanding shares and own 1.36% of the company stock.
Largest 10 shareholders include CITIGROUP INC (85.3K shares), XTX Topco Ltd (74.2K shares), Virtu Financial LLC (59.3K shares), LPL Financial LLC (56.1K shares), VERUS CAPITAL PARTNERS, LLC (43K shares), VANGUARD GROUP INC (30.9K shares), GEODE CAPITAL MANAGEMENT, LLC (27.5K shares), Cambridge Investment Research Advisors, Inc. (12.8K shares), BlackRock, Inc. (12.4K shares), and TRUIST FINANCIAL CORP (10.5K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.